Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206933 | 0.95 | ENPP2 (0.47) | ENPP2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL5212575 | 0.94 | ENPP2 (0.49) | ENPP2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL5209943 | 0.92 | ENPP2 (0.47) | ENPP2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL5212903 | 0.91 | ENPP2 (0.46) | ENPP2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL5206854 | 0.91 | ENPP2 (0.44) | ENPP2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL5208698 | 0.91 | TP53 (0.46) | ENPP2MAPTTP53LMNAMEN1 | |
| SCHEMBL5208185 | 0.90 | ENPP2 (0.42) | ENPP2MAPTTP53MKNK2LMNA | |
| SCHEMBL5213638 | 0.89 | ENPP2 (0.42) | ENPP2MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL5211199 | 0.89 | MAPT (0.53) | ENPP2ATMMAPTTP53LMNA | |
| SCHEMBL5213091 | 0.89 | ENPP2 (0.42) | ENPP2MAPTTP53LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | ENPP2 2808/4885MKNK1 3524/4885ATM 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.